Brouwer, Philip J. M.
Antanasijevic, Aleksandar
de Gast, Marlon http://orcid.org/0000-0003-3976-8183
Allen, Joel D.
Bijl, Tom P. L.
Yasmeen, Anila
Ravichandran, Rashmi
Burger, Judith A.
Ozorowski, Gabriel http://orcid.org/0000-0002-9695-8138
Torres, Jonathan L.
LaBranche, Celia http://orcid.org/0000-0002-6653-6655
Montefiori, David C.
Ringe, Rajesh P.
van Gils, Marit J.
Moore, John P.
Klasse, Per Johan
Crispin, Max http://orcid.org/0000-0002-1072-2694
King, Neil P.
Ward, Andrew B. http://orcid.org/0000-0001-7153-3769
Sanders, Rogier W. http://orcid.org/0000-0002-2324-8573
Funding for this research was provided by:
Bill and Melinda Gates Foundation (OPP1132237, OPP1111923, INV-008352/OPP1153692, OPP1153692, OPP1132237)
Bill and Melinda Gates Foundation
EC | Horizon 2020 Framework Programme (681137, 681137)
amfAR, The Foundation for AIDS Research (109514-61-RKVA)
Bill and Melinda Gates Foundation
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (P01 AI110657, AI144462)
Bill and Melinda Gates Foundation
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
Bill and Melinda Gates Foundation
Article History
Received: 30 September 2020
Accepted: 7 January 2021
First Online: 9 February 2021
Competing interests
: N.P.K. is a co-founder, shareholder, and chair of the scientific advisory board of Icosavax, Inc. All other authors declare no competing interests.